Volcano Corp.
Medtronic and Volcano form sales pact
Volcano lands tentative win in CardioSpectra lawsuit
Did a last-minute visit from med-tech CEOs change Rep. Tsongas’ mind on device tax vote?
It would be a stretch to call it an offer she couldn’t refuse, but in the end what choice did Rep. Niki Tsongas (D-Mass.) have but to consider the pleas of the men in her Capitol Hill office last Thursday?
Tsongas represents a stretch of Massachusetts that runs from the edge of Natick to the tip of New Hampshire and includes the lion’s share of the I-495 beltway, where you can’t throw a trocar without hitting a company that either makes a medical device or services a medical device company.
St. Jude Medical wins CE Mark, launches Enlightn renal denervation system | MassDevice.com On Call
MASSDEVICE ON CALL —St. Jude Medical (NYSE:STJ) landed CE Mark approval and announced commercial launch for its Enlightn renal denervation system as a treatment for hypertension.
Volcano kills it in Japan, gains Street cred
Volcano’s (NSDQ:VOLC) Q1 earnings came in just shy of Wall Street analysts’ expectations as operating costs kept pace with a robust uptick in revenues.
Revenues during the 3 months ended March 31 grew 11.6% to $90.4 million, compared with $81 million during the same period last year, driven by some big boosts in regional sales.
Boston Scientific launches Pluromed’s BackStop kidney stone treatment | Wall Street Beat
Boston Scientific (NYSE:BSX) launched its BackStop kidney stone treatment product in the U.S. and certain international markets this week.
Report: Medtronic to shutter Ventor’s Israeli shop | Wall Street Beat
Medtronic (NYSE:MDT) is shutting down heart valve maker Ventor Technologies, which it acquired in 2009, and moving its R&D efforts to other site, according to an Israeli business journal.
Netanya, Israel-based Ventor is developing an aortic replacement valve called the Engager. Medtronic bought the company for $325 million 3 years ago.
Analyst: CRM market “bad as it’s ever been” | Wall Street Beat
The cardiac rhythm management market is "about as bad as it has ever been," according to an analyst with Gabelli & Co., due in part to headwinds from a federal probe and a negative journal article.
VCs press Senate on “IPO On Ramp” bill | Wall Street Beat
The National Venture Capital Assn. is spearheading a drive to get a bill through the U.S. Senate that would make it easier for small companies to raise money by going public.
The "IPO On Ramp" measure would ease the regulatory requirements for IPOs and temporarily reduce the reporting burdens imposed by the Sarbanes-Oxley Act.
Edwards to re-state financials | Wall Street Beat
Edwards Lifesciences (NYSE:EW) said it will re-state its financial results for the first 3 quarters of 2011, “due to certain technical errors in the balance sheets and cash flow statements for these interim periods.”
The Irvine, Calif.-based heart valve maker said the errors involve the mis-statement of short-term investments as cash & equivalents, plus the way it treated tax benefits from stock plans.